title: Widespread increases in malondialdehyde immunoreactivity in dopamine-rich and dopamine-poor regions of rat brain following multiple, high doses of methamphetamine.
abstract: Treatment with multiple high doses of methamphetamine (METH) can induce oxidative damage, including dopamine (DA)-mediated reactive oxygen species (ROS) formation, which may contribute to the neurotoxic damage of monoamine neurons and long-term depletion of DA in the caudate putamen (CPu) and substantia nigra pars compacta (SNpc). Malondialdehyde (MDA), a product of lipid peroxidation by ROS, is commonly used as a marker of oxidative damage and treatment with multiple high doses of METH increases MDA reactivity in the CPu of humans and experimental animals. Recent data indicate that MDA itself may contribute to the destruction of DA neurons, as MDA causes the accumulation of toxic intermediates of DA metabolism via its chemical modification of the enzymes necessary for the breakdown of DA. However, it has been shown that in human METH abusers there is also increased MDA reactivity in the frontal cortex, which receives relatively fewer DA afferents than the CPu. These data suggest that METH may induce neuronal damage regardless of the regional density of DA or origin of DA input. The goal of the current study was to examine the modification of proteins by MDA in the DA-rich nigrostriatal and mesoaccumbal systems, as well as the less DA-dense cortex and hippocampus following a neurotoxic regimen of METH treatment. Animals were treated with METH (10 mg/kg) every 2 h for 6 h, sacrificed 1 week later, and examined using immunocytochemistry for changes in MDA-adducted proteins. Multiple, high doses of METH significantly increased MDA immunoreactivity (MDA-ir) in the CPu, SNpc, cortex, and hippocampus. Multiple METH administration also increased MDA-ir in the ventral tegmental area and nucleus accumbens. Our data indicate that multiple METH treatment can induce persistent and widespread neuronal damage that may not necessarily be limited to the nigrostriatal DA system.
authors: Division of Basic Medical Sciences, Mercer University School of Medicine Macon, GA, USA.
authors: Kristen A
authors: KA
authors: Horner
authors: Yamiece E
authors: YE
authors: Gilbert
authors: Susan D
authors: SD
authors: Cline
references: J Neurosci. 1991 Jul;11(7):2209-16
references: 1712381
references: Proc Natl Acad Sci U S A. 2004 Sep 21;101(38):13891-6
references: 15353588
references: Brain Res. 1999 Dec 18;851(1-2):76-86
references: 10642830
references: Neuropsychopharmacology. 1991 Jan;4(1):71-5
references: 2003868
references: J Med Chem. 2000 Nov 2;43(22):4169-79
references: 11063613
references: Neurotoxicology. 2004 Jan;25(1-2):101-15
references: 14697885
references: J Pharmacol Exp Ther. 2006 Nov;319(2):703-9
references: 16857724
references: J Pharmacol Exp Ther. 2001 Feb;296(2):520-7
references: 11160639
references: DNA Cell Biol. 2003 May;22(5):329-38
references: 12941160
references: Brain Res Rev. 2009 May;60(2):379-407
references: 19328213
references: Pharmacol Rev. 2007 Jun;59(2):125-50
references: 17379813
references: J Neurochem. 1995 Jul;65(1):192-200
references: 7790860
references: Ann N Y Acad Sci. 1998 May 30;844:92-102
references: 9668667
references: Pharmacol Ther. 2003 Jul;99(1):45-53
references: 12804698
references: Nature. 1981 Feb 12;289(5798):537-42
references: 6258083
references: Neuropharmacology. 1992 Apr;31(4):315-21
references: 1381816
references: J Pharmacol Exp Ther. 1980 Aug;214(2):257-62
references: 6104722
references: Proc Natl Acad Sci U S A. 1994 Aug 2;91(16):7772-6
references: 8052659
references: Br J Pharmacol. 1977 Jun;60(2):270P-271P
references: 880439
references: Brain Res. 2003 Nov 7;989(2):205-13
references: 14556942
references: Brain Res. 1998 Nov 30;813(1):200-2
references: 9824698
references: Chem Res Toxicol. 2009 May;22(5):835-41
references: 19388687
references: Neuroscience. 1995 Nov;69(2):441-57
references: 8552240
references: Neuropharmacology. 2000 Jan 28;39(3):399-406
references: 10698006
references: Med Res Rev. 2007 Nov;27(6):817-68
references: 17044003
references: Neuropharmacology. 1983 Oct;22(10):1165-9
references: 6606137
references: J Neurosci. 2004 Jun 30;24(26):6028-36
references: 15229250
references: J Pharmacol Exp Ther. 1998 Oct;287(1):107-14
references: 9765328
references: Eur J Pharmacol. 1976 Apr;36(2):363-71
references: 6286
references: Free Radic Res. 1998 Jun;28(6):659-71
references: 9736317
references: J Neurosci. 1999 Feb 15;19(4):1484-91
references: 9952424
references: J Neurochem. 2002 Sep;82(6):1472-9
references: 12354295
references: Arch Gen Psychiatry. 1989 Mar;46(3):243-50
references: 2784046
references: Neurochem Res. 2009 Apr;34(4):786-94
references: 19023656
references: J Neurochem. 2002 Nov;83(3):645-54
references: 12390526
references: Trends Cogn Sci. 2000 Jun;4(6):215-222
references: 10827444
references: J Histochem Cytochem. 1979 Dec;27(12):1657
references: 392001
references: Crit Rev Neurobiol. 2005;17(2):87-117
references: 16808729
references: Synapse. 1996 Aug;23(4):328-34
references: 8855518
references: Neuropharmacology. 1981 Dec;20(12A):1135-40
references: 6172742
references: J Neurochem. 2005 Oct;95(2):429-36
references: 16086684
references: Brain Res. 1980 Jul 7;193(1):153-63
references: 7378814
references: Nature. 1976 Mar 18;260(5548):257-8
references: 1256566
references: Am J Psychiatry. 2001 Mar;158(3):383-9
references: 11229978
references: Chem Res Toxicol. 2001 Sep;14(9):1184-92
references: 11559032
references: J Pharmacol Exp Ther. 2006 Oct;319(1):414-21
references: 16840646
references: Brain Res. 1983 Sep 26;275(2):321-8
references: 6626985
references: J Pharmacol Exp Ther. 2006 Aug;318(2):676-82
references: 16687477
references: J Neurochem. 2001 Oct;79(1):152-60
references: 11595767
references: Nutr Metab Cardiovasc Dis. 2005 Aug;15(4):316-28
references: 16054557
references: Curr Opin Psychiatry. 2005 May;18(3):235-42
references: 16639146
references: Annu Rev Neurosci. 1999;22:105-22
references: 10202533
references: FASEB J. 2003 Oct;17(13):1775-88
references: 14519657
references: Neuropsychopharmacology. 2002 Oct;27(4):565-75
references: 12377393
references: Eur J Neurosci. 2006 Sep;24(5):1385-94
references: 16987223